Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FibroGen PHD2 compound 13
- Development stage
- Unknown
- Lead developer
- FibroGen
01
Overview
FibroGen PHD2 compound 13: sourced facts only. name: "Building on a previous discovery that HIF-PH inhibitors can enhance HSC mobilization in combination with G-CSF, we optimized 13 to exhibit high PHD2 potency, improved solubility, and an optimized PK profile." [PMID:40047531]; target: "Building on a previous discovery that HIF-PH inhibitors can enhance HSC mobilization in combination with G-CSF, we optimized 13 to exhibit high PHD2 potency, improved solubility, and an optimized PK profile." [PMID:40047531]; developer: "FibroGen Inc., 409 Illinois Street, San Francisco, California 94154, United States." [PMID:40047531]; stage: "13 was effective at enhancing G-CSF-induced HSC mobilization in mice at a dose of 2 mg/kg." [PMID:40047531]
02
Targets
EGLN1 (Prolyl hydroxylase domain-containing protein 2)
Beyond the preview
Go deeper on FibroGen PHD2 compound 13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FibroGen PHD2 compound 13.